Valuation: Capricor Therapeutics, Inc.

Market Cap 483M 438M 405M 365M 689M 45.09B 716M 4.88B 1.93B 24.33B 1.81B 1.77B 76.87B P/E 2026 *
-3.37x
P/E 2027 * -5.75x
Enterprise Value 483M 438M 405M 365M 689M 45.09B 716M 4.88B 1.93B 24.33B 1.81B 1.77B 76.87B EV / Sales 2026 *
36.4x
EV / Sales 2027 * 7.27x
Free-Float
88.15%
Yield 2026 *
-
Yield 2027 * -
1 day+3.98%
1 week-3.55%
Current month+34.09%
1 month+28.65%
3 months+14.83%
6 months-69.46%
Current year-70.36%
1 week 8.19
Extreme 8.19
11.23
1 month 5.67
Extreme 5.67
11.23
Current year 2.96
Extreme 2.96
36.82
1 year 2.96
Extreme 2.96
40.37
3 years 2.87
Extreme 2.87
40.37
5 years 2.56
Extreme 2.56
40.37
10 years 0.88
Extreme 0.88
42.5
Manager TitleAgeSince
Chief Executive Officer 62 20/11/2013
Director of Finance/CFO 40 01/01/2018
Chief Tech/Sci/R&D Officer - 13/05/2025
Director TitleAgeSince
Chairman 70 01/11/2013
Director/Board Member 68 20/11/2013
Director/Board Member 79 20/11/2013
Date Insider Type Main position Quantity % Market Cap. Importance
26/5/26 Free

CHIEF COMMERCIAL OFFICER

80,000 0.1383%
18/5/26 Exercice

Chief Financial Officer

6,000 0.0104%
13/5/26 Exercice

Chairman

7,874 0.0136%
Change 5-day change 1-year change 3-year change Capi.($)
+3.86%-3.55%+50.35%+181.41% 483M
+1.15%-2.81%+53.73%+71.00% 65.56B
-2.64%-1.13%+7.82%+88.90% 60.41B
-1.07%+0.30%+22.91%+86.76% 55.76B
+0.05%-2.92%+9.29%+120.25% 46.98B
-2.25%-6.12%+19.52%+26.14% 43.63B
-0.70%+1.43%+14.05%+45.20% 36.7B
-2.61%-15.94%+134.73%+660.85% 36.09B
-0.77%-2.21%+77.27%+57.96% 32.9B
-1.18%+1.21%-38.73%+387.27% 26.96B
Average -0.59%-3.11%+35.09%+172.58% 41B
Weighted average by Cap. -1.00%-1.50%+33.20%+146.99%

Financials

2026 *2027 *
Net sales 13.26M 12.03M 11.12M 10.03M 18.93M 1.24B 19.66M 134M 52.98M 668M 49.73M 48.69M 2.11B 66.37M 60.25M 55.66M 50.21M 94.79M 6.2B 98.42M 671M 265M 3.35B 249M 244M 10.57B
Net income -145M -131M -121M -109M -207M -13.52B -215M -1.46B -578M -7.3B -543M -531M -23.05B -87.77M -79.68M -73.61M -66.4M -125M -8.2B -130M -887M -351M -4.43B -329M -322M -13.98B
Net Debt - -
Projected Income Statement - Annual - Capricor Therapeutics, Inc.
Logo Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
Employees
231
Date Price Change Volume
18/11/26 USD 8.555 +3.07% 3,465,445
16/11/26 USD 8.300 -12.91% 3,919,851
13/11/26 USD 9.530 -6.93% 3,666,024
12/11/26 USD 10.24 -8.73% 4,779,308
11/11/26 USD 11.22 +26.49% 10,070,073
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Capricor Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
8.300USD
Average target price
27.25USD
Spread / Average Target
+228.31%
  1. Stock Market
  2. Stocks
  3. CAPR Stock